This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
18
Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
Placebo will be administered orally
Neumora Investigator Site
Phoenix, Arizona, United States
Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7- point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. Thus, scores in the MADRS range from 0 to 60, with increasing scores indicating increasing severity.
Time frame: Baseline and up to Week 6
Change from Baseline to Week 6 assessed in the Snaith-Hamilton Pleasure Scale (SHAPS) total score
The SHAPS is a 14-item participant-reported instrument which measures anhedonia. It has been shown to be valid and reliable in normal and clinical samples, with adequate construct validity, satisfactory test-retest reliability, and high internal consistency. The scale will be completed by the participant and reviewed by site personnel qualified to oversee completeness. Each of the 14 items has a set of 4 responses, 2 of which endorse agreement (Definitely Agree, Agree) and 2 of which endorse disagreement (Disagree, Strongly Disagree). A total score can be derived by summing the response items; where those answered with "strongly agree" will be coded as a 1, while a "strongly disagree" response will be coded as 4. Therefore, scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
Time frame: Baseline and up to Week 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neumora Investigator Site
Little Rock, Arkansas, United States
Neumora Investigator Site
Garden Grove, California, United States
Neumora Investigator Site
Long Beach, California, United States
Neumora Investigator Site
San Jose, California, United States
Neumora Investigator Site
Torrance, California, United States
Neumora Investigator Site
Gainesville, Florida, United States
Neumora Investigator Site
Lauderhill, Florida, United States
Neumora Investigator Site
Maitland, Florida, United States
Neumora Investigator Site
Miami, Florida, United States
...and 11 more locations